The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. RemeGen Co's Revenue for the
three
months ended in Dec. 2025 was €184.5 Mil. RemeGen Co's average Accounts Receivable for the
three
months ended in Dec. 2025 was €47.3 Mil.
Hence, RemeGen Co's Receivables Turnover for the
three
months ended in Dec. 2025 was 3.90.
RemeGen Co (FRA:REG) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
RemeGen Co Receivables Turnover Related Terms
RemeGen Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for RemeGen Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:REG vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, RemeGen Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RemeGen Co Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RemeGen Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where RemeGen Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RemeGen Co (FRA:REG) has a Receivables Turnover of 3.90 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on RemeGen Co and its competitors. According to the industry distribution chart, RemeGen Co ranks #389 out of 840 companies in the Biotechnology industry, placing it in the top 46.3%.
Is RemeGen Co's Receivables Turnover too high?
RemeGen Co's current Receivables Turnover is 3.90. The Biotechnology industry median Receivables Turnover is 5.30. RemeGen Co's value of 3.90 is 26.4% below this industry median. Based on the distribution chart, RemeGen Co ranks #389 out of 840 companies in the Biotechnology industry, which is above the industry midpoint. Overall, RemeGen Co has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RemeGen Co ranks #389 out of 840 companies for Receivables Turnover. This puts RemeGen Co in the upper half of its industry. The industry median Receivables Turnover is 5.30. RemeGen Co's value of 3.90 is 26.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.30, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RemeGen Co's current Receivables Turnover of 3.90 is 26.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on RemeGen Co and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RemeGen Co's current Receivables Turnover is 3.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (FRA:REG) is currently considered Possible Value Trap. The stock's GF Value™ is €15.27, compared to a current price of €9.36 — trading 38.7% below its estimated fair value. The current Receivables Turnover is 3.90 and 26.4% below the Biotechnology industry median of 5.30. RemeGen Co's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For RemeGen Co (FRA:REG), the current Receivables Turnover is 3.90 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RemeGen Co (FRA:REG) Overvalued in 2026?
Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued.
The current stock price of €9.36 is trading 38.7% below its estimated GF Value™ of €15.27.
GuruFocus considers RemeGen Co to be Possible Value Trap.
Key valuation signals for FRA:REG:
Receivables Turnover: 3.90
GF Value™: €15.27 vs. price of €9.36 (38.7% below fair value)
Industry Position: 26.4% below the Biotechnology median (#389 of 840)
No single metric tells the full story. See the FRA:REG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
39GF Score
Get the complete analysis for FRA:REG
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:REG has been successfully added to your 
